Yousif Capital Management LLC Purchases 1,652 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Yousif Capital Management LLC increased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 14.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,954 shares of the company’s stock after purchasing an additional 1,652 shares during the quarter. Yousif Capital Management LLC’s holdings in TransMedics Group were worth $808,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC raised its stake in shares of TransMedics Group by 33.7% during the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after acquiring an additional 219 shares in the last quarter. National Bank of Canada FI lifted its holdings in shares of TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares during the last quarter. Quarry LP increased its holdings in shares of TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after buying an additional 316 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its position in TransMedics Group by 3.8% in the fourth quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock valued at $548,000 after buying an additional 322 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Canaccord Genuity Group lowered their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Oppenheimer reissued an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Robert W. Baird dropped their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Finally, TD Cowen reduced their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Trading Up 1.3 %

NASDAQ TMDX opened at $72.18 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a 50-day simple moving average of $65.87 and a 200-day simple moving average of $106.78. The firm has a market capitalization of $2.42 billion, a PE ratio of 76.79 and a beta of 2.12.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.00% of the stock is currently owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.